Efficacy and Safety of Ruxolitinib Cream Combined With Narrow-Band UVB Phototherapy for Treatment of Vitiligo
Document Type
Journal Article
Publication Date
12-10-2025
Journal
The Journal of investigative dermatology
DOI
10.1016/j.jid.2025.11.016
Keywords
Combination therapy; JAK inhibitor; NB-UVB; repigmentation; safety
Abstract
Ruxolitinib cream and narrow-band UVB phototherapy (NB-UVB) independently promote repigmentation in patients with vitiligo. This exploratory phase 2 study evaluated the efficacy and safety of adding NB-UVB to ruxolitinib cream therapy. Patients (≥12 years) with nonsegmental vitiligo and depigmented areas ≤10% total body surface area applied 1.5% ruxolitinib cream monotherapy twice daily to depigmented areas. At Week 12, patients with <25% improvement from baseline in total Vitiligo Area Scoring Index (
APA Citation
Pandya, Amit G.; Lynde, Charles W.; Alam, Maryam Shayesteh; Thorla, Ira H.; Reed, Katherine; Green, Lawrence J.; Soltanalizadeh, Babak; Stefani-Hunyady, Diana; Kornacki, Deanna; and Amster, Mark S., "Efficacy and Safety of Ruxolitinib Cream Combined With Narrow-Band UVB Phototherapy for Treatment of Vitiligo" (2025). GW Authored Works. Paper 8418.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/8418
Department
Dermatology